Semaglutide: Promotes weight loss by reducing appetite and caloric intake via GLP-1 receptor activation Trevogrumab: Blocks myostatin, a protein that limits muscle growth, thereby promoting muscle mass increase Garetosmab: Inhibits activin A, AB, and AC, which are also negative regulators of muscle mass, further supporting muscle growth and fat reduction Clinical Trial Findings Phase 2 COURAGE Trial Design: Randomized, double-blind, with multiple arms including semaglutide alone, semaglutide plus trevogrumab (high/low dose), and semaglutide plus trevogrumab and garetosmab
Nature (1973) 245(5424):3235
Food and Drug Administration (FDA) prescribing information, Centers for Disease Control and Prevention (CDC) data, and peer-reviewed research from the National Library of Medicine (PubMed), but individual responses may vary
The real question is not whether to offer access
For context on how triple-agonist mechanisms compare to growth-hormone-related peptides in the research space, the tesamorelin vs sermorelin is a useful reference for understanding how different hormonal axes influence body composition
